Reviewing Pluristem Therapeutics (NASDAQ:PSTI) & Qiagen (NASDAQ:QGEN)
Pluristem Therapeutics (NASDAQ:PSTI) and Qiagen (NYSE:QGEN) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, valuation, analyst recommendations and dividends.
This is a breakdown of recent ratings for Pluristem Therapeutics and Qiagen, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Earnings and Valuation
This table compares Pluristem Therapeutics and Qiagen’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Pluristem Therapeutics||$50,000.00||1,197.40||-$26.12 million||($2.50)||-1.56|
|Qiagen||$1.50 billion||5.13||$190.38 million||$1.34||25.50|
Qiagen has higher revenue and earnings than Pluristem Therapeutics. Pluristem Therapeutics is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Pluristem Therapeutics has a beta of 0.89, meaning that its stock price is 11% less volatile than the S&P 500. Comparatively, Qiagen has a beta of 0.83, meaning that its stock price is 17% less volatile than the S&P 500.
Insider and Institutional Ownership
6.0% of Pluristem Therapeutics shares are held by institutional investors. Comparatively, 65.0% of Qiagen shares are held by institutional investors. 6.7% of Pluristem Therapeutics shares are held by insiders. Comparatively, 9.0% of Qiagen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
This table compares Pluristem Therapeutics and Qiagen’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Qiagen beats Pluristem Therapeutics on 10 of the 14 factors compared between the two stocks.
About Pluristem Therapeutics
Pluristem Therapeutics Inc., together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. The company develops PLacental eXpanded (PLX) cell therapy products, including PLX-PAD cells, which is Phase III clinical trial for the treatment of critical limb ischemia (CLI) in patients ineligible for revascularization, recovery after surgery for hip fracture, and acute radiation syndrome (ARS), as well as peripheral and cardiovascular, and orthopedic diseases. It also develops PLX-R18 cells that is in Phase I clinical trial for incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as conducts various animal studies for the evaluation of PLX-R18 for the treatment of ARS. The company has collaborative research agreement with the Berlin-Brandenburg Center for Regenerative Therapies; a license and commercialization agreement for conducting clinical trials and commercialization of its PLX-PAD product in South Korea related to the treatment CLI and intermediate claudication; and nTRACK, a collaborative project with Leitat to examine gold nano particles labeling of stem cells. It also has a collaboration agreement with the NASA's Ames Research Center to evaluate the potential of PLX cell therapies in preventing and treating medical conditions caused during space missions. Pluristem Therapeutics Inc. was founded in 2001 and is based in Haifa, Israel.
QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers sample technologies for plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, target enrichment, and library preparation for sequencing applications; and assay technology solutions. It also provides Ingenuity Variant Analysis, an application for analysis and interpretation of human sequencing data generated with next-generation sequencing (NGS) technologies; QIAGEN Clinical Insight, an evidence-based variant classification; CLC Genomics Workbench for the analysis and visualization of data from various NGS platforms; and GeneGlobe, a Web-based portal that enables researchers to search and order bioinformatics solutions and linking biological interpretation from pre-designed and custom PCR assay kits, NGS assay panels, and other products. In addition, the company offers instrumentation systems for laboratories. Its automation platforms include QIAsymphony, a modular system; QIAsymphony SP for sample preparation; QIAsymphony AS for assay setup; Rotor-Gene Q, a rotary real-time PCR cycler system; QIAstat-Dx for molecular analysis of common syndromes; GeneReader NGS System, a sample to insight NGS solution for laboratories to deliver actionable results; NeuMoDx 288 and NeuMoDx 96 for automation of higher-throughput PCR testing in clinical laboratories; and QIAcube and QIAcube connect workstations, which provides versatile solutions for automated sample processing; It serves molecular diagnostics, applied testing, pharma, and academia customers. QIAGEN N.V. has collaboration agreements with Ares Genetics and Laboratory Corporation of America Holdings. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.
Receive News & Ratings for Pluristem Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.